Patients’ characteristics at vaccination
| All n=64 | Rituximab n=22 | Methotrexate n=16 | Immunosuppressive drugs n=19 | Others n=7 | |
| Age, years | |||||
| Median (IQR) | 52 (37.8–66.3) | 58.5 (48.3–67.8) | 50 (38.5–72.3) | 34 (30–53.5) | 51 (44–58.5) |
| >50 year, n (%) | 35 (54.7) | 16 (72.7) | 8 (50) | 7 (36.8) | 4 (57) |
| Female, n (%) | 48 (75) | 15 (68.2) | 11 (68.8) | 15 (79) | 7 (100) |
| Diagnosis | |||||
| Vasculitis | |||||
| ANCA-associated vasculitis | 18 (28.1) | 18 (81.8) | 0 | 0 | 0 |
| Behçet’s | 2 (1.6) | 0 | 0 | 2 (10.5) | 0 |
| Cryoglobulinemia vasculitis | 2 (1.6) | 2 (9.1) | 0 | 0 | 0 |
| Large vessel vasculitis | 4 (6.3) | 0 | 4 (25) | 0 | 0 |
| Connective tissue disease | |||||
| Systemic lupus erythematosus | 15 (23.4) | 0 | 4 (25) | 9 (47.4) | 2 (28.6) |
| Systemic sclerosis | 7 (10.9) | 1 (4.5) | 0 | 4 (21.1) | 2 (28.6) |
| Sjogren syndrome | 2 (1.6) | 1 (4.5) | 1 (6.3) | 0 | 0 |
| Myositis | 5 (7.8) | 0 | 3 (18.8) | 2 (10.5) | 0 |
| Inflammatory rheumatic diseases* | 3 (4.7) | 0 | 2 (12.5) | 0 | 1 (14.3) |
| Sarcoidosis | 3 (4.7) | 0 | 1 (6.3) | 1 (5.3) | 1 (14.3) |
| Others | 3 (4.7) | 0 | 1 (6.3) | 1 (5.3) | 1 (14.3) |
| Disease duration (years), mean (SD) | 9.5 (9) | 9.2 (9.1) | 10.1 (8) | 8.4 (8.9) | 12 (11.9) |
| Disease activity status | |||||
| Active disease, n (%) | 17 (26.5) | 4 (18.2) | 6 (37.5) | 7 (36.8) | 0 (0) |
| Renal involvement, n (%) | 19 (29.7) | 9 (41) | 3 (18.8) | 6 (31.6) | 1 (14.3) |
| Ongoing treatments, n (%) | |||||
| Prednisone | 45 (70.3) | 13 (59.1) | 12 (75) | 17 (89.5) | 3 (42.9) |
| Median, mg/day (IQR) | 7.5 (5–15) | 5 (5–13.8) | 7.5 (5–13.8) | 10 (5–25) | 5 (5–12.5) |
| cDMARDs | |||||
| Methotrexate | 19 (29.7) | 3 (13.6) | 16 (100) | 0 | 0 |
| Azathioprine | 5 (7.8) | 0 | 0 | 5 (26.3) | 0 |
| Mycophenolate mofetil | 12 (18.8) | 0 | 0 | 12 (63.2) | 0 |
| Cyclophosphamide | 3 (4.7) | 1 (4.5) | 0 | 2 (10.5) | 0 |
| Biological therapies | |||||
| Anti-TNF-α | 6 (9.4) | 0 | 1 (6.3) | 3 (15.8) | 2 (28.6) |
| Rituximab | 22 (34.4) | 22 (100) | 0 | 0 | 0 |
| Tocilizumab | 3 (4.7) | 0 | 3 (18.8) | 0 | 0 |
| Belimumab | 1 (1.6) | 0 | 1 (6.3) | 0 | 0 |
| Hydroxychloroquine | 15 (23.4) | 2 (9.1) | 4 (25) | 7 (36.8) | 2 (28.6) |
| No DMARDs, biologics or prednisone | 1 (1.6) | – | – | – | 1 (14.3) |
| Number of lines of previous treatments, n, median (IQR) | 2 (1–3.8) | 2 (1–4.3) | 2 (1–4) | 2 (1–3) | 2 (1–2) |
*Inflammatory rheumatic diseases: rheumatoid arthritis (n=2), spondyloarthritis (n=1).
cDMARDs, conventional disease-modifying antirheumatic drugs; TNF-α, tumour necrosis factor.